YRIV (YRIV) Stock Price & Analysis
YRIV (YRIV) rose 0.00% to USD 0 as of July 26, 2026 at 14:52 UTC, according to Nexqual real-time market data.
YRIV last closed at USD 0; the session ranged USD 0–0 on volume of 6,100 shares. Market capitalization is $53,858, with a 52-week range of USD 0–0.01 (PNK). Source: Nexqual, July 26, 2026 at 14:52 UTC.
Key Statistics (as of July 26, 2026 at 14:52 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.01 |
| Volume | 6,100 shares |
| Market Cap | $53,858 |
| Exchange | PNK |
Technical Analysis (YRIV)
Nexqual's technical model rates YRIV "NEUTRAL" based on 2 bullish and 2 bearish signals across 125 daily candles, as of July 26, 2026 at 14:52 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 37.5 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (YRIV)
Wall Street analysts rate YRIV "None", per Nexqual as of July 26, 2026 at 14:52 UTC.
| Consensus Rating | None |
|---|
Earnings (YRIV)
Source: Nexqual, July 26, 2026 at 14:52 UTC.
Financials & Fundamentals (YRIV)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -6.29% |
| Debt / Equity | 72.28 |
| Current Ratio | 5.96 |
| Total Cash | $5.37M |
| Total Debt | $115.25M |
| Free Cash Flow | $12.91M |
Source: Nexqual, July 26, 2026 at 14:52 UTC.
Financial Health Score (YRIV)
Nexqual rates YRIV's overall financial health "Weak" across five dimensions, as of July 26, 2026 at 14:52 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Strong — $5M cash vs $115M debt |
| Cash Flow | Weak — Operating cash flow -$4M |
| Efficiency | Critical — ROE -6%, ROA -0.2% |
Ownership (YRIV)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 179.53M |
| Float | 87.67M |
| Short % of Float | +0.31% |
Source: Nexqual, July 26, 2026 at 14:52 UTC.
Leadership (YRIV)
YRIV is led by Xiangyao Liu (age 52), CEO, President, Secretary & Chairman, per Nexqual as of July 26, 2026 at 14:52 UTC.
| CEO, President, Secretary & Chairman | Xiangyao Liu (age 52) |
|---|---|
| Chief Financial Officer | Tsz-Kit Chan (age 49) |
| Executive Director | James Stuart Coleman (age 68) |
| Executive Director | Zhanhuai Cheng (age 76) |
| Executive Director | Yanliang Wu (age 58) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PRPO | Precipio, Inc. | USD 23.68 | ▲ 0.85% |
| BPTH | Bio-Path Holdings, Inc. | USD 0.04 | ▲ 0% |
| PRTO | RCN Pareto Strategic Allocation | USD 27.17 | ▼ 1.14% |
| AKTX | Akari Therapeutics Plc | USD 8.7 | ▼ 11.31% |
| VIVE | Viveve Medical, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 14:52 UTC. This page is informational and not investment advice.